hVIVO Publishes 2025 Annual Report and Sets May AGM Date

Open Orphan Plc ( (GB:HVO) ) has shared an update.

hVIVO plc has published its Annual Report and Accounts for the year ended 31 December 2025 and circulated its Notice of Annual General Meeting to shareholders. The documents, including proxy materials, are now available on the company’s website for investor review.

The Annual General Meeting will take place on 13 May 2026 at DAC Beachcroft’s offices in the City of London, giving shareholders a formal opportunity to vote on company matters and review performance. The scheduling and publication of these materials mark a routine, but important, step in hVIVO’s corporate governance and investor communication cycle as it continues to position itself as a key clinical development partner for global biopharma clients.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on HVO Stock

According to Spark, TipRanks’ AI Analyst, HVO is a Outperform.

Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.

To see Spark’s full report on HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a UK‑based, full‑service international clinical development partner and the global leader in human challenge trials, working with seven of the world’s ten largest biopharma companies. The Group offers an end‑to‑end platform from preclinical strategy through first‑in‑human and Phase II patient trials to specialist virology and immunology lab services, leveraging large volunteer databases and owned facilities in the UK and Germany.

Through four integrated service lines – Consulting, Clinical Trials, Human Challenge Trials, and Laboratories – hVIVO accelerates clinical proof‑of‑concept for vaccines and other medicines. Its London quarantine unit, billed as the world’s largest of its kind, enables controlled viral exposure studies, while FluCamp supports specialist recruitment and long‑term biobanking underpins both challenge studies and standalone client research.

Average Trading Volume: 3,420,986

Technical Sentiment Signal: Sell

Current Market Cap: £58.17M

For a thorough assessment of HVO stock, go to TipRanks’ Stock Analysis page.